Lurbinectedin showed clinical benefit across therapy lines in SCLC, with best responses seen in later lines and with prior immunotherapy exposure. The post Second-Line & Later Therapies Show Promising Outcomes […]
The post Second-Line & Later Therapies Show Promising Outcomes in Small Cell Lung Cancer first appeared on Blackandmed .
